Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors

• Chemotherapy refractory HER-2-positive breast cancer, gastric cancer, non-small cell lung cancer, and chemotherapy resistant or relapsed ovary cancer.
• Relapsed patients after anti-HER-2 using antibody or kinase inhibitor therapy.
• Patients must be 18 years of age or older.
• Patients must have an ECOG (Eastern Cooperative Oncology Group )performance status of 0-2.
• Patients must have evidence of adequate bone marrow reserve, hepatic and renal function as evidenced by the following laboratory parameters:

Absolute neutrophil count greater than 1500/mm3. Platelet count greater than 100,000/mm3. Hemoglobin greater than 10g/dl (patients may receive transfusions to meet this parameter).

Total bilirubin \< 1.5 times upper limits of normal. Serum creatinine less than or equal to 1.6 mg/ml or the creatinine clearance must be greater than 70 ml/min/1.73m(2).

• Seronegative for HIV antibody.
• Seronegative for active hepatitis B, and seronegative for hepatitis C antibody.
• Patients must be willing to practice birth control during and for four months following treatment.NOTE:women of child-bearing age must have evidence of negative pregnancy test.
• Patients must be willing to sign an informed consent.

Exclusion Criteria:

• Patients with life expectancy less than 12 months will be excluded.
• Patients with uncontrolled hypertension (> 160/95), unstable coronary disease evidenced by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (> New York Heart Association Class II), or myocardial infarction within 6 months of study will be excluded.
• Patients with any of the following pulmonary function abnormalities will be excluded: FEV(forced expiratory volume), \< 30% predicted; DLCO (diffusing capacity of lung for carbon monoxide) \< 30% predicted (post-bronchodilator); Oxygen Saturation less than 90% on room air.
• Patients with severe liver and kidney dysfunction or consciousness disorders will be excluded.
• Pregnant and/or lactating women will be excluded.
• Patients with active infections, including HIV, will be excluded, due to unknown effects of the vaccine on lymphoid precursors.
• Patients with any type of primary immunodeficiencies will be excluded from the study.
• Patients requiring corticosteroids (other than inhaled) will be excluded.
• Patients with history of T cell tumors will be excluded.
• Patients who are participating or participated any other clinical trials in latest 30 days will be excluded.